Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin

NCT01911468 · Completed

Last updated 2026-05-28

This clinical trial tested whether adding the medication liraglutide to metformin helps reduce body weight in women with polycystic ovary syndrome (PCOS) and obesity.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 36 people

Who can join Ages 18–55 · female only

Timeline Started 2011-11 · est. completion 2013-04

Where 1 site · Slovenia

What this study is testing ClinicalTrials.gov NCT01911468 ↗

Description as written by the study sponsor.

The purpose of this study was to determine whether combined treatment with liraglutide and metformin is more effective than liraglutide or metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (PCOS) who had been previously poor responders regarding weight reduction on metformin monotherapy. We anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with liraglutide or metformin.

Treatments tested

metformin also known as Glucophage tablets Drug
liraglutide also known as Victoza 6 mg/ml solution for injection in pre-filled pen Drug
metformin and liraglutide also known as Glucophage tablets and Victoza 6 mg/ml solution for injection in pre-filled pen Drug

Main thing measured	The main outcome was change in body weight.
Sponsor	University Medical Centre Ljubljana
Conditions studied	PCOS, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01911468 ↗